article · Computational and Structural Biotechnology Journal
Understanding viral evolution and predicting future mutations are crucial for overcoming drug resistance and developing long-lasting treatments. Previously, we established machine learning (ML) models using dynamic residue network (DRN) metric data and leveraging a vast amount of existing mutation data from the SARS-CoV-2 main protease (M<sup>pro</sup>). Here, we sought to assess the generalizability and robustness of the current models across other SARS-CoV-2 proteins. To achieve this, for the first time, we employed a transfer learning (TL) approach, allowing us to determine the extent to which M<sup>pro</sup> trained models could be applied to other SARS-CoV-2 proteins. The TL results were highly promising, with artificial neural network (ANN) and random forest (RF) correlation coefficients for M<sup>pro</sup> closely matching those of NSP10, NSP16, and PL<sup>pro</sup>. The ANN |R| value for M<sup>pro</sup> was 0.564, while NSP10, NSP16, and PL<sup>pro</sup> had values of 0.533, 0.527, and 0.464, respectively. Similarly, the RF |R| value for M<sup>pro</sup> was 0.673, compared to 0.457, 0.460, and 0.437 for NSP10, NSP16, and PL<sup>pro</sup>, respectively. Interestingly, we did not observe a strong correlation for the spike (S) protein monomer and its domains. The low p-values that are associated with the correlation |R| values show that the linear correlations between predicted and actual mutation frequencies are statistically significant. This indicates that TL may generalize well across structurally related viral proteins using DRN-derived ML model from M<sup>pro</sup>. Overall, we aim to develop a universal ML model for predicting missense mutation frequencies in viral proteins, and this study lays the foundation for that goal.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1016/j.csbj.2025.04.029
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.